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Abstract
The glycoproteins and glycolipids of the cell surface have sugar chains that normally
terminate in a sialic acid residue, but inflammatory activation of myeloid cells can
cause sialidase enzymes to remove these residues, resulting in desialylation and
altered activity of surface receptors, such as the phagocytic complement receptor
3 (CR3). We found that activation of microglia with lipopolysaccharide (LPS), fibrillar
amyloid beta (Aβ), Tau or phorbol myristate acetate resulted in increased surface
sialidase activity and desialylation of the microglial surface. Desialylation of microglia
by adding sialidase, stimulated microglial phagocytosis of beads, but this was
prevented by siRNA knockdown of CD11b or a blocking antibody to CD11b
(a component of CR3). Desialylation of microglia by a sialyl-transferase inhibitor
(3FAx-peracetyl-Neu5Ac) also stimulated microglial phagocytosis of beads. Desialylation
of primary glial-neuronal co-cultures by adding sialidase or the sialyl-transferase inhibitor
resulted in neuronal loss that was prevented by inhibiting phagocytosis with cytochalasin
D or the blocking antibody to CD11b. Adding desialylated microglia to glial-neuronal cul-
tures, in the absence of neuronal desialylation, also caused neuronal loss prevented by
CD11b blocking antibody. Adding LPS or Aβ to primary glial-neuronal co-cultures caused
neuronal loss, and this was prevented by inhibiting endogenous sialidase activity with
N-acetyl-2,3-dehydro-2-deoxyneuraminic acid or blockage of CD11b. Thus, activated
microglia release a sialidase activity that desialylates the cell surface, stimulating
CR3-mediated phagocytosis of neurons, making extracellular sialidase and CR3 potential
treatment targets to prevent inflammatory loss of neurons.
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1 | INTRODUCTION
Microglia are macrophages resident in the central nervous system
(CNS), and are the main mediators of inflammation and phagocytosis
in the CNS. They are of myeloid origin and therefore related to phago-
cytes in the periphery (Saijo & Glass, 2011). Microglia defend the brain
against invading pathogens, but also engulf and remove apoptotic
neurons, necrotic neurons, debris, protein aggregates, synapses and
axons (Rabinowicz & Courten-Myers, 1996; Vilalta & Brown, 2018).
Microglia phagocytose less-active synapses during development to
shape neuronal networks, and too little of this “synaptic pruning” may
contribute to autism, and too much pruning may contribute to schizo-
phrenia (Neniskyte & Gross, 2017; Sekar et al., 2016). During neurode-
generative diseases, such as Alzheimer's disease, excessive microglial
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phagocytosis of synapses and live neurons may cause the neu-
rodegeneration (Vilalta & Brown, 2018). Thus, it is important to under-
stand howmicroglial phagocytosis is regulated.
Microglial phagocytosis can be activated by exposure to inflamma-
tory stimuli such as bacterial lipopolysaccharide (LPS). LPS stimulates
microglia to express and release complement components C1q and C3,
which can opsonize by binding amyloid, synapses or neurons and
encouraging microglia to phagocytose such tagged targets via the
microglial complement receptor 3 (CR3). CR3 is an integrin receptor,
consisting of CD11b and CD18, detecting iC3b-opsonized targets, and
is a phagocytic receptor mediating microglial phagocytosis of synapses
and dendrites (Linnnartz, Kopatz, Tenner, & Neumann, 2011; Schafer
et al., 2012). CR3 can be regulated by “inside-out” activation via binding
of cytoplasmic proteins inducing a conformational change in the extra-
cellular ligand binding site (Takagi, Petre, Walz, & Springer, 2002). How-
ever, activation of neutrophils results in desialylation of CR3, which
stimulates its ability to bind to ligands (Feng et al., 2011). This suggests
that CR3 can be activated “outside-in” by desialylation, or more gener-
ally that in inflammatory conditions phagocytic receptors may be
“licensed” to operate by desialylation (Feng et al., 2011).
Sialic acids are a family of structurally-related and negatively-
charged monosaccharides, which typically terminate the N-glycans of
membrane-bound proteins or glycolipids when linked to the penulti-
mate galactose residue via α2,3- or α2,6-linkage. Sialic acids constitute
the main negative charge of the cell surface, and regulate cell attach-
ment and interactions via multiple mechanisms (Schauer, 1985; Varki,
1997). The removal of these terminal sialic acid residues is termed
“desialylation” and, in mammals, can be mediated by four different
sialidase/neuraminidase isoenzymes (Neu1-Neu4). Neu1 has been
reported on the surface of mature macrophages (Liang et al., 2006)
and activated neutrophils (Feng et al., 2011), and this activity can
increase phagocytic signaling (Seyrantepe et al., 2010).
Desialylation of neurons promotes binding of C1q and C3b, which
in turn encourages microglia to phagocytose dendrites via CR3
(Linnnartz et al., 2011). Mutations of sialyl-transferase genes result in
desialylation and multiple diseases of brain development and function
in humans, and knockout of homologous genes in mice results in exten-
sive loss of myelin, dendrites and neurons (Yoo et al., 2015). This was
suggested to be as a result of desialylation of neurons and myelin, but
could equally be due to changes in sialylation of microglia. We recently
found that LPS stimulated BV-2 microglia to release a sialidase activity
that desialylates co-cultured cells (Nomura, Vilalta, Allendorf, Hornik, &
Brown, 2017). However, the functions and implications of this activity
on the microglial cell surface are unknown. More generally, it is not
known whether sialylation of the microglial surface changes in inflam-
matory conditions, and whether changes in microglial sialylation affect
microglial function.
Here we demonstrate that primary microglial cells undergo des-
ialylation after exposure to a variety of stimuli: LPS, fibrillar amyloid
beta (Aβ), phorbol 12-myristate 13-acetate (PMA) and rTAU protein.
Importantly, removal of sialic acid residues on microglial cells enhances
their ability to phagocytose and this was blocked by knockdown of
CD11b. In neuronal-glial co-cultures desialylation induces neuronal loss
that is inhibited by a blocking antibody against CD11b. Moreover, the
sialidase inhibitor N-acetyl-2,3-dehydro-2-deoxyneuraminic acid (DANA)
blocked neuronal loss in LPS- or Aβ-stimulated neuronal-glial cultures.
These results indicate novel ways of blocking microglia phagocytosis and
inflammatory neuronal loss.
2 | MATERIALS AND METHODS
2.1 | Materials
All cell culture reagents were from Invitrogen (Paisley, UK). All
chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless
indicated otherwise. Neuraminidase from Clostridium perfringens was
from Sigma-Aldrich. 3-FAx-peracetyl-Neu5Ac was from Merck
Millipore (Burlington, MA). Carboxylated Nile red 5 μm beads were
from Spherotech (Chicago, IL). CD11b-targeting, nontargeting siRNA,
Lipofectamine 3000 reagent and mouse IgG2a isotype control were
purchased from Thermo Scientific (Waltham, MA). Mouse monoclonal
anti-CD11b (clone OX-42) antibody was from Serotec AbD (Hercules,
CA). Recombinant human Tau protein (isoform 2N4R) was a kind gift
from Dr Vilmante Borutaite. FITC-labeled human fibrinogen was from
Molecular Innovations (Novi, MI).
2.2 | Cell culture and treatments
All experiments were performed in accordance with the U.K. Animals
(Scientific Procedures) Act (1986) and approved by the Cambridge
University local ethical committee. The immortalized microglial cell
line BV-2 were maintained as previously described (Blasi, Barluzzi,
Bocchini, Mazzolla, & Bistoni, 1990). Glial cultures were prepared
from postnatal Days 5–7 rat cortex. Mixed neuronal-glial co-cultures
were from 5 to 7 day old rat or mouse cerebella. The extraction and
cultivation of both these cultures are described elsewhere (Neher
et al., 2011). LPS from Salmonella enterica serotype typhimurium was
added at 100 ng/mL for 24 or 72 hr where indicated. Aβ 1–42
(Anaspec (Fremont, CA)) was prepared as previously described and
fibrilized over 24 hr at 37C. Fibrillar Aβ was used at 3 μM for 24 hr
or 1 μM for 72 hr as indicated. PMA was used at 1 μM final concen-
tration. 2N4R Tau protein was used at 1.5 μM over 24 hr. Exo-
sialidase from C. perfringens was added at 200 mU/mL for 1 hr prior
to the phagocytosis assays. For long term treatments in mixed
neuronal-glia cultures sialidase was added at 80 mU/mL. Desialylation
by the sialyl-transferase inhibitor 3-FAx-peracetyl-Neu5Ac was
achieved by adding the inhibitor 1 or 2 days to primary or BV-2 cul-
tures, respectively (both at 100 μM).
Neuronal-glial co-cultures were treated with the sialyl-transferase
inhibitor at 80 μM for 3 days. DMSO was used a vehicle in these
experiments. CD11b blocking or isotype control antibodies were added
at 5 μg/mL in bead-uptake experiments 1 hr prior to desialylation. In
mixed neuronal-glial experiments CD11b or isotype control and cyto-
chalasin D (3 μg/mL and 1 μM final concentration, respectively) were
added at 2 day of the treatments. For neuronal-glial experiments with
added microglia, microglia were either desialylated by pretreatment
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with 100 μM sialyl-transferase inhibitor for 1 day in co-culture with
astrocytes, or by pretreatment with C. perfringens sialidase at 200 mU/
mL for 1 hr. Desialylated microglia were added at 60,000 cells per
treated well in presence of CD11b or isotype control antibody. Neuro-
nal loss was evaluated 24 hr post-treatment. Sialidase inhibitor DANA
was added for 3 days to mixed neuronal-glial cultures at 400 μM.
2.3 | Neuraminidase activity assay
Endogenous neuraminidase activity on BV-2 or primary microglia was
assessed by an Amplex Red Neuraminidase Assay Kit (Life Technolo-
gies, Carlsbad, CA) following the manufacturer's instructions. Briefly,
1 × 105 cells were cultured in phenol red-free DMEM and treated
accordingly. Twenty-four hours post-treatment cells were washed with
warm phenol red-free DMEM and then subjected to a reagent mix
containing 50 μM Amplex Red reagent, 0.1 unit/mL HRP, 2 unit/mL
galactose oxidase (from Dactylium dendroides) and 250 μg/mL fetuin
(from fetal calf serum) in reaction buffer containing 50 mM Tris–HCl
(pH 7.2) and 1 mM CaCl2 for 30 minutes at 37C. Fluorescence was
measured on an Optima Plate Reader (BMG Technologies, Aylesbury,
UK) with 530 nm excitation and 590 nm emission detection.
2.4 | Desialylation staining and fibrinogen binding
Desialylation was also detected by staining cells with FITC-coupled
peanut agglutinin (PNA-FITC). Briefly, detached cells were incubated
at 5 μg/mL PNA-FITC in PBS for 30 min at room temperature, washed
in PBS and then taken to flow cytometry. Similarly, binding of human
FITC-labeled fibrinogen to microglia was assessed as follows. Cells
were incubated with 100 μg/mL labeled fibrinogen in PBS for 30 min
at room temperature and washed in PBS. Binding was assessed by
flow cytometry by measuring the mean FL1 intensity of at least 5,000
events.
2.5 | siRNA-mediated knockdown
BV-2 cells at 70–80% confluency were subjected to a lipid:siRNA mix
containing 3% (v/v) Lipofectamine 3000 (Thermo Fischer, Waltham,
MA) and 60 pmol of either CD11b targeting or scrambled siRNA
(Silencer Select siRNA, Thermo Fischer) in serum-free OptiMEM.
Transfection medium was removed after 3 hr incubation at 37C and
replaced by DMEM containing 10% FBS. This procedure was repeated
24 hr after the first transfection. Twenty-four hours after the second
transfection BV-2 cells were re-seeded at appropriate density in low-
serum DMEM. At this point RNA was extracted (see below). Phagocy-
tosis assays were typically performed on the following day.
2.6 | Bead phagocytosis assays
Fluorescent 5 μm beads were added at 0.005% (w/v) to cells and left
for 3 or 1 hr to BV-2 or primary cells, respectively. Media was aspi-
rated and cells washed several times with cold PBS. Uptake of beads
into cells was assessed by flow cytometry (Accuri C6 BD) or by
imaging with an epifluorescent microscope (Leica DM16000 CS). For
cytometry, cells were lifted by trypsinization and re-suspended in
PBS. At least 5,000 cells were analyzed for each treatment replicate.
Bead-uptake could be observed in FL-3 due to the coupling of the
beads to the Nile red dye. For each experiment the percentage of cells
containing beads was calculated and normalized to the vehicle-treated
condition. For microscopy, cells were stained for Hoechst 33342
(5 μg/mL) and four microscopic fields per well with at least two wells
were quantified. Uptake was calculated by counting beads within cells
over total numbers of cells.
2.7 | RNA isolation and RT-qPCR
Whole RNA was isolated 24 hr postsecond siRNA treatment using
Monarch Total RNA Miniprep Kit (NEB, Ipswich, MA). Using the Super-
Script II Reverse Transcriptase Kit (Invitrogen) 1 μg of total RNA was
converted into cDNA using random hexamer primers. qPCR was carried
out with the Platinum SYBR Green qPCR SuperMix (Invitrogen). Primer
pair sequences for CD11b were fwd 50ATGGACGCTGATGGCAATACC
and rev 50TCCCCATTCACGTCTCCCA. Samples were amplified and
measured in a Rotor-Gene Q cycler (Qiagen, Hilden, Germany). Data
was analyzed with the Rotor-Gene Q software. Comparative concen-
trations were normalized by the housekeeping gene β-actin to correct
for different efficiencies of reverse transcription.
2.8 | Cell density measurements
Cell densities were quantified in cultures at 3 day post-treatment. Cul-
tures were subjected to nuclear stain Hoechst 33342 (5 μg/mL) and
microglial stain Alexa 488-tagged Isolectin GS-IB4 from Griffonia
simplicifolia (1 μg/mL). Healthy and apoptotic (chromatin-condensed)
neurons were recognized by their distinct nuclear morphology. Per
well four microscopic fields were quantified for a single experiment
with n = 2 wells per condition.
2.9 | Statistical analysis
Analysis of data was performed using Graphpad Prism (version 6.0)
and data shown represented as a mean of at least n = 3 independent
experiments ± SEM. Statistical significance was assessed by ANOVA
followed by Tukey's or Sidak's post hoc test or by t tests where indi-
cated. p-Values of p ≤ .05 are considered significant.
3 | RESULTS
3.1 | Activation of microglia in vitro results in
desialylation of microglia and sialidase activity on the
surface of primary rat microglia
We previously found that microglial BV-2 cells have increased
sialidase activity on the cell surface when stimulated with bacterial
LPS (Nomura et al., 2017), so we tested here whether primary rat
microglia have increased sialidase activity when activated by a variety
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of inflammatory stimuli. We found that primary rat microglia incubated
with LPS, PMA, fibrillar Aβ and TAU protein have increased sialidase
activity on the microglial surface (Figure 1a). Sialidase activity can cause
desialylation, so we tested whether LPS, PMA, fibrillar Aβ and TAU
would promote desialylation of the microglial cell surface. Desialylation
was measured by the binding of peanut agglutinin (PNA) to the cells, as
PNA binds galactose residues and this binding is blocked by sialylation.
Indeed, we found that all these inflammatory stimuli induced an
increase in binding of PNA to the microglia (Figure 1b), indicating des-
ialylation of the cell surface.
3.2 | Direct desialylation of microglia by a sialidase
or sialyl-transferase inhibitor increases phagocytosis
of 5 μm beads
To investigate the impact of sialylation on microglial phagocytosis, we
used the sialidase enzyme from C. perfringens or an inhibitor of sialyl-
transferase enzymes, 3FAx-peracetyl-Neu5Ac (ST-Inh), to effectively
desialylate BV-2 or primary microglia. One hour treatment of BV-2
microglia with the sialidase enzyme or 1–2 day incubation with the
sialyl-transferase inhibitor led to strong binding of PNA to the
microglia (sixfold increase ±0.3 SEM for sialidase, ninefold increase
±0.4 for ST-Inh vs. vehicle), indicating a large decrease in sialylation
(Figure 2a). To determine whether desialylation affected the phago-
cytic behavior of microglial cells, we incubated the cells with 5 μm
beads (fluorescent and carboxylated). We observed an increase in the
phagocytosis of beads by desialylated BV-2 (sialidase: 2.1 ± 0.1-fold
increase, ST-Inh: 1.5 ± 0.1-fold increase) and primary microglia (two-
fold increase ±0.1 SEM for sialidase, 1.7 ± 0.2-fold increase for ST-Inh)
compared to vehicle-treated conditions (Figure 2b,c). Thus, des-
ialylation of microglia, whether induced by stimulating desialylation or
inhibiting sialylation, induces an increase in microglial phagocytosis.
3.3 | Knockdown or blockage of CD11b reduces
sialidase-induced phagocytosis, and desialylation of
microglia increases binding of CR3 ligand fibrinogen
CR3 is a key phagocytic receptor of microglia, composed of CD18 and
CD11b, which is known to be regulated by sialylation in neutrophils
(Feng et al., 2011). So, we tested whether CD11b was involved in the
(a) (b)
F IGURE 1 Activation of primary rat microglia stimulates cell surface sialidase activity and results in surface desialylation. (a) Surface
neuraminidase (Neu) activity was measured on live rat primary microglia after 24 hr of exposure to fibrillar amyloid beta (Aβ, 3 μM), phorbol
myristate acetate (PMA, 1 μM), lipopolysaccharide (LPS, 100 ng/mL) or Tau protein (2N4R isoform, 1.5 μM). Data presented as mean fluorescence
signal from individual experiments (n = 3). Statistical analysis was performed by paired t tests. *p < .05, **p < .01. (b) Binding of the FITC-
conjugated lectin peanut agglutinin (PNA) to primary rat microglia as measured by flow cytometry in the FL-1 channel. Data presented as mean
fluorescence intensities from n = 3 individual experiments. Statistical analysis was performed by paired t tests, *p < .05
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sialidase-induced increase in phagocytosis. Using a siRNA-mediated
knockdown approach we achieved efficient ablation of CD11b mRNA
in BV-2 microglia (Figure 3b). Interestingly, upon depletion of CD11b,
we did not observe a sialidase-induced increase in phagocytosis in
BV-2 cells as compared to a nontargeting siRNA control (Figure 3a).
Similarly, when blocking CD11b with a blocking antibody, we entirely
prevented the sialidase-induced increase in bead phagocytosis by pri-
mary rat microglia. (Figure 3c). Thus, CR3 appears to be responsible
for the increase in phagocytosis induced by desialylation of microglia.
To further confirm the involvement of CR3 in this pathway we tested
the binding of a classic CR3 ligand, fibrinogen (Wright et al., 1988), to
microglia. We found that desialylated microglia bound more FITC-
labeled human fibrinogen than vehicle-treated microglia (Figure 3d).
3.4 | Direct desialylation of glial-neuronal co-cultures
by sialidase or sialyl-transferase inhibitor results in
neuronal loss, prevented by blocking CD11b or
phagocytosis
Because desialylation of microglia stimulates phagocytosis, we won-
dered whether it would stimulate microglial phagocytosis of neurons.
To assess the effect of desialylation on phagocytosis of live neurons,
we determined the effect of adding a sialidase or sialyl-transferase
inhibitor to glial-neuronal co-cultures derived from rat or mouse
cerebella. As shown in Figure 4a, when desialylated with either sialyl-
transferase inhibitor or sialidase we observed a significant reduction
in neuronal density after 3 days (from 100 to 75 ± 1% healthy neu-
rons for sialyl-transferase inhibitor, and to 75 ± 5% healthy neurons
for sialidase). This neuronal loss was prevented by adding an inhibitor
of phagocytosis, cytochalasin D (CytoD), on Day 2 of the treatment
(90 ± 3% healthy neurons for sialyl-transferase inhibitor plus CytoD,
and 86 ± 5% healthy neurons for CytoD and sialidase). CytoD alone
slightly increased the number of apoptotic neurons, indicating some
toxicity, but CytoD also increased the number of live neurons in the
presence of sialidase or sialyl-transferase inhibitor (Figure 4a, gray
bars), indicating that desialylation results in microglial phagocytosis of
live neurons. In order to test whether this phagocytosis was mediated
by CD11b, we added the CD11b-blocking antibody to the co-cultures
and found that blocking CD11b prevented the loss of neurons
induced either by stimulating desialylation or inhibiting sialylation
(Figure 4b). A IgG2a isotype control was used to control for any
unspecific binding, and had no effect (Figure 4b).
To assess if the observed effects were due to desialylation of
microglia rather than desialylation of neurons, we added desialylated
primary rat microglia to the glial-neuronal co-cultures. Indeed, we
found that addition of microglia pretreated with either sialidase or
sialyl-transferase inhibitor induced neuronal loss that could be blocked
by co-treatment with CD11b antibody (Figure 4d). Thus, desialylation
of microglia, in the absence of desialylation of neurons, was sufficient
to induce neuronal loss mediated by CR3.
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F IGURE 2 Direct desialylation of microglia by
a sialidase or sialyl-transferase inhibitor increases
phagocytosis of 5 μm beads. (a) FITC-conjugated
lectin peanut agglutinin (PNA-FITC) binding to
sialidase treated or sialyl-transferase inhibitor (ST-
Inh)-treated BV-2 microglia. Data presented
as mean FL-1 fluorescence values, with error bars
presenting SEM of at three independent
experiments. Statistical analysis was performed
by one-way ANOVA with Tukey's post hoc test,
****p < .0001. (b) Phagocytic uptake of 5 μm
beads by BV-2 microglia. (c) Phagocytic uptake
of 5 μm beads by primary rat microglia. Data
presents the percentage of cells containing beads
normalized to the vehicle condition. Error bars
represent SEM of three independent experiments.
Statistical analysis was performed by one-way
ANOVA with Sidak's post hoc test **p < .01,
***p < .001, ****p < .0001
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3.5 | LPS- or Aβ-induced neuronal loss in glial-
neuronal co-cultures, prevented by a sialidase inhibitor
DANA or by a CD11b-blocking antibody
As LPS induced a sialidase activity and desialylation of microglia
(Figure 1), and sialidase-induced desialylation of microglia caused
phagocytosis of live neurons (Figure 4), we tested whether LPS could
induce neuronal loss via sialidase activity. As expected, addition of
LPS or fibrillar Aβ to neuronal-glial co-cultures for 3 days resulted in
neuronal loss, without increasing neuronal death (Figure 5). Co-
treatment with the sialidase inhibitor DANA at 400 μM completely
prevented this loss, again without increasing neuronal death
(Figure 5a,b). This indicated that LPS and Aβ induce neuronal loss via
an extracellular sialidase activity (as DANA does not enter cells), and
thus extracellular sialidases may be treatment targets to prevent
inflammatory neuronal loss. Moreover, addition of CD11b-blocking
antibody prevented LPS- or Aβ-induced neuronal loss (Figure 5c), indi-
cating the involvement of CD11b in this inflammatory neuronal loss.
4 | DISCUSSION
In the fields of macrophage and neutrophil biology, the regulation of
functions such as phagocytosis and cell adhesion by cell surface neur-
aminidase is widely accepted (Sakarya et al., 2004; Seyrantepe et al.,
2010). However, this has not previously been investigated in
microglia. Previously, we have shown that BV-2 microglia present a
desialylating activity on their cell surface when stimulated with the
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F IGURE 3 Knockdown or blockage of CD11b reduces sialidase-induced phagocytosis in BV-2 cells and primary rat microglia, respectively.
(a) Uptake of 5 μm bead into BV-2 microglia that were pretreated with nontargeting (NT) or CD11b targeting siRNA. Phagocytic uptake was
measured in three independent knockdown experiments and data normalized to nontargeting siRNA (si-NT). Error bars represent SEM. Statistical
analysis was performed by one-way ANOVA with Tukey's post hoc test, *p < .5 versus si-NT control, #p < .5 versus si-NT sialidase. (b) CD11b
expression 48 hr after siRNA mediated knockdown of CD11b. Data was normalized by beta-actin gene expression and measurements represent
three independent knockdown experiments with error bars representing SEM. Statistical analysis was performed with an unpaired t test,
**p < .01. (c) Uptake of beads in primary microglia after stimulation with sialidase in the presence or absence of blocking antibody CD11b or
isotype control. N = 3 independent phagocytosis assays with error bars representing SEM. Statistical analysis was performed by one-way ANOVA
with Tukey's post hoc test, **p < .01 versus isotype + control treatment, ##p < .01 versus sialidase + anti-CD11b treatment. (d) Binding of FITC-
labeled human fibrinogen to vehicle treated or desialylated primary rat microglia. Data presented as mean fluorescence values of three
independent binding assays. Statistical analysis was performed by repeat measure (RM) one-way ANOVA followed by Sidak's post hoc
test, *p < .05
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TLR-4 agonist LPS (Nomura et al., 2017). In this study, we show that
primary microglia activated by LPS, Aβ, TAU or PMA have increased
surface sialidase activity and a substantial desialylation of the surface.
In order to model the potential effects of sialidase activity and
desialylation of the cell surface, we treated BV-2 or primary rat
microglia with desialylating reagents. Both exogenous sialidase and
3-FAx-peracetyl-Neu5Ac were effective at desialylating microglia,
as measured by an increase of PNA binding. Microglial des-
ialylation stimulated microglial phagocytosis of 5 μm carboxylated
beads (mimicking the size and charge of cells). A recent study
ve
hic
le
ST
-In
h
sia
lid
as
e
ve
hic
le
ST
-In
h
sia
lid
as
e
0
50
100
ne
ur
on
al
 d
en
si
ty
 
(%
 D
M
SO
 +
 v
eh
ic
le
)
**** ****
Live NeuronsApoptotic
### &&
DMSO Cyto D
ve
hic
le
ST
-In
h
sia
lid
as
e
ve
hic
le
ST
-In
h
sia
lid
as
e
0
50
100
ne
ur
on
al
 d
en
si
ty
 
(%
 is
ot
yp
e 
+ 
ve
hi
cl
e)
**** ****
#### &&&&
isotype CD11b
Live NeuronsApoptotic
ve
hic
le
ST
-In
h
sia
lid
as
e
ve
hic
le
ST
-In
h
sia
lid
as
e
0
50
100
ne
ur
on
al
 d
en
si
ty
 
(%
 is
ot
yp
e 
+ 
ve
hi
cl
e)
**** ****
#### &&&&
isotype CD11b
Live NeuronsApoptotic
Hoechst IB4 merge
vehicle
sialidase
ST-Inh
(a)
(c)
(d)(b)
F IGURE 4 Desialylation causes neuronal loss in glial-neuronal co-cultures, which is prevented by blockage of phagocytosis or CD11b. (a and
b) Neuronal densities of a mouse (a) and rat (b) neuronal-glial co-cultures with indicated treatments. Neurons were counted 3 days after
application of desialylating agents ± cytochalasin D (Cyto D) (a) or antibodies (b) added at Day 2 of the treatment. Gray bars represent the
percentage of apoptotic neuronal nuclei. Mean neuronal densities of three independent cultures were quantified and normalized to vehicle
condition. Error bars represent SEM. Statistical analysis was performed by two-way ANOVA with Sidak's post hoc test. ****p < .0001 versus
vehicle treatment, ###p < .001 versus sialyl-transferase inhibitor (ST-Inh) treatment, &&p < .01 versus sialidase treatment. (c) Representative
images of glial-neuronal co-cultures imaged 3 days after vehicle, sialidase or ST-Inh treatment. Cells were stained with nuclei-staining dye
Hoechst 33342 (cyan) and microglia-staining dye Isolectin-B4-Alexa 488 (IB4, green) and visualized at ×20 magnification. (d) Neuronal densities
of neuronal-glial co-cultures that were treated with desialylated (either by ST-Inh or sialidase) primary rat microglia. Approximately 60,000
microglia were added to each well ± CD11b neutralizing antibody or isotype control, and neuronal density assessed 1 day later. Data presented
as mean of three independent experiments ± SEM. Statistical analysis was performed by two-way ANOVA with Sidak's post hoc test.
****p < .0001 versus isotype + vehicle, ####p < .0001 versus isotype + ST-Inh, &&&&p < .0001 versus isotype + sialidase [Color figure can be
viewed at wileyonlinelibrary.com]
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(Pluvinage et al., 2019) found that desialylation of BV-2 cells stim-
ulated phagocytosis of beads, and this was attributed to Siglec-2
(sialic acid-binding immunoglobulin-type lectin, CD22) inhibiting
phagocytosis when microglia are sialylated, but losing this inhibitory
activity when microglia are desialylated. Whether CD22 regulates
phagocytosis via CR3 is unknown. Siglec-3 (CD33) has been proposed
to have similar inhibitory role to Siglec-2 (CD22), regulated by sialylation
(Bradshaw et al., 2013). The finding that multiple receptors appear to
monitor the sialylation state of the microglial surface supports the idea
that this sialylation status changes and is important for microglial
function.
We found that microglial desialylation increases microglial phago-
cytosis, and that this increased phagocytosis is mediated by CR3. For
example, depletion of CD11b, the alpha-subunit of the CR3 integrin,
blocked sialidase-induced phagocytosis of beads. And blocking
CD11b with a blocking antibody in primary microglia also completely
prevented the sialidase-induced phagocytosis. And microglia treated
with sialyl-transferase inhibitor or sialidase bound more fibrinogen,
consistent with activation of CR3. However, we did not test whether
the effect of microglial desialylation on CR3 is direct (i.e., due to des-
ialylation of CR3 itself) or indirect (e.g., due to inside-out activation of
CR3). The possibility that desialylation of CR3 itself causes the
increased phagocytosis is consistent with literature evidence that acti-
vated neutrophils desialylate CD11b and CD18, which apparently
activates CR3 binding to ligands (Feng et al., 2011). Thus, there is the
possibility that CR3 might be outside-in activated by sialylation. How-
ever, CR3 can be inside-out activated by multiple signal transduction
pathways (Abram & Lowell, 2009) that might be affected by microglial
desialylation. Thus, further research is required to determine whether
microglial desialylation activates CR3 directly or indirectly.
To test whether desialylation of microglia might induce phagocytosis
of live neurons, we induced desialylation of neuronal-glial co-cultures.
We found a decrease in neuronal density after treatment with either a
sialidase or a sialyl-transferase inhibitor, which was blocked by an inhibi-
tor of phagocytosis cytochalasin D. This indicated that desialylation
induced phagocytosis of live neurons. A confounding factor in this exper-
iment is, however, that desialylation of astrocytes and neurons is occur-
ring, as well as microglia. Desialylated neurites are known to be targeted
(a) (b)
(c)
F IGURE 5 Blockage of sialidase or CD11b
prevents LPS- or Aβ-induced neuronal loss.
Neuronal densities of mouse-derived neuronal-
glial co-cultures that were co-treated with
100 ng/mL lipopolysaccharide (LPS) (a) or 1 μM
fibrillar amyloid beta (Aβ) (b) and pan-sialidase
inhibitor N-acetyl-2,3-dehydro-
2-deoxyneuraminic acid (DANA, 400 μM) for
3 days. Mean neuronal densities of three
independent cultures were quantified and
normalized to vehicle condition. Error bars
represent SEM. Statistical analysis was performed
by two-way ANOVA with Sidak's post hoc test,
****p < .0001, ####p < .0001 versus LPS (a) or Aβ
(b). (c) Neuronal densities from rat derived
neuronal-glial co-cultures that were treated for
3 days with LPS (100 ng/mL) or fibrillar Aβ (1 μM).
At Day 2 of treatment either isotype control or
CD11b-blocking antibody were added to the
cultures and densities assessed at Day 3. Data
presented as mean neuronal densities of three
independent cultures, normalized to vehicle
+ isotype control (±SEM). Statistical analysis was
performed by two-way ANOVA followed by
Sidak's post hoc test, *p < .05, ***p < .001 versus
isotype + vehicle, ####p < .0001 versus isotype
+ LPS, &&&p < .001 versus isotype + Aβ
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by microglial phagocytosis (Linnnartz et al., 2011; Wielgat & Braszko,
2012). Note, however, that we induced desialylation with an exo-
sialidase, whereas Linnnartz et al., 2011; Wielgat & Braszko, 2012 also
added endo-sialidase to remove 2,8-linked poly-sialic acids, which are
known to inhibit phagocytosis (Wang & Neumann, 2010). To confirm
that desialylation of microglia triggers neuronal loss, we desialylated pri-
mary rat microglia using sialidase or sialyl-transferase inhibitor and added
these microglia to neuronal-glial co-cultures. We observed a significant
reduction in neuronal cell number after 1 day of co-culture with these
desialylated microglia, and this neuronal loss was blocked by co-
treatment with the CD11b antibody. This indicates that CD11b is
involved in the removal of neurons from primary cultures by desialylated
microglia. However, it is important to note that desialylation (of neurons
or microglia) can activate microglial phagocytosis of neurons or neuronal
parts (neurophagy) by multiple potential mechanisms, including:
(a) increased deposition and activity of complement C1q and C3b
(Linnnartz et al., 2011), (b) increased binding of opsonin galectin-3
(Nomura et al., 2017), (c) decreased trans-activation of inhibitory Siglec-
11 (Wang & Neumann, 2010), Siglec-F (Wielgat & Braszko, 2012) and
Siglec-E (Claude, Linnartz-Gerlach, Kudin, Kunz, & Neumann, 2013), and
(d) possibly decreased cis-activation of inhibitory Siglec-2 (CD22;
Pluvinage et al., 2019) and Siglec-3 (CD33; Bradshaw et al., 2013).
As LPS- or Aβ-induced microglial desialylation, and desialylation
induced neuronal loss, we tested whether LPS- or Aβ-induced neuro-
nal loss via sialidase activity in neuronal-glial co-cultures. Both LPS
and Aβ are known to induce loss of neurons in these cultures via
phagocytosis of live neurons (Neher, Neniskyte, & Brown, 2012;
Neniskyte, Neher, & Brown, 2011). Here we show that we can pre-
vent this neuronal loss by co-treatment with the sialidase inhibitor
DANA. Similarly, blockage of CD11b prevents the loss seen when
treating with LPS or Aβ. This suggests that LPS- and Aβ-induced
neuronal loss is mediated by activation of CD11b by an extracellu-
lar sialidase activity. Therefore, inhibition of this sialidase activity
is a potential treatment target to prevent inflammation-induced
neuronal loss.
Mutations of sialyl-transferase genes cause multiple diseases of
brain development in humans, and knockout of homologous genes in
mice cause loss of myelin, dendrites and neurons (Yoo et al., 2015).
This has been suggested to be caused by the desialylation of myelin
and neurons, but the results reported here suggest that desialylation
of microglia might also contribute to excessive microglial phagocytosis
of neurons and potentially myelin and synapses. Synaptic pruning dur-
ing development is thought be mediated by microglial CR3 (Schafer
et al., 2012), and therefore is potentially regulated by microglial des-
ialylation. And excessive synaptic pruning during development may
contribute to cognitive impairments and schizophrenia (Sekar et al.,
2016), and this is potentially linked to desialylation as educational
attainment, cognitive ability, maths ability and/or schizophrenia are
associated with genetic variants in sialidases Neu1 and Neu2, and
sialyl-transferases ST3GAL2, ST3GAL3, ST6GAL2, ST8SIA1, ST8SIA2
and ST8SIA4 (https://genetics.opentargets.org). One mechanism by
which these enzymes may be regulating brain development and func-
tion is by changing the sialylation status of microglia.
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